ANTIEPILEPTIC DRUGS

PRENATAL VALPROATE AND RISK OF AUTISM

Investigators at Aarhus University Hospital, Denmark; and Centers for Disease Control, Atlanta, GA, conducted a population-based study of all children born alive in Denmark from 1996 to 2006 to determine the risk of autism spectrum disorders (ASD) and childhood autism (CA) in children exposed to valproate during pregnancy. [ASD includes CA, Asperger syndrome, atypical autism, and pervasive developmental disorders]. The Danish Psychiatric Central Register was used to identify children diagnosed for the first time with ASD and with CA. The National Hospital Register was used to identify children diagnosed with congenital malformations and parents diagnosed with epilepsy. Of 655,615 children born from 1996-2006, 5437 were identified with ASD, including 2067 with CA. The mean age of the children at end of follow-up was 8.84 years (range 4-14 years). The estimated absolute risk of ASD after 14 years of follow-up was 1.53% for ASD and 0.48% for CA. In the overall cohort, the 508 children exposed to valproate had an absolute risk of 4.42% for ASD and 2.50% for CA. In the 6584 children born to women with epilepsy, the absolute risk of ASD among 432 children exposed to valproate was 4.15%, and the risk of CA was 2.95%. In comparison, the risk among 6152 children not exposed to valproate was 2.44% for ASD and 1.02% for CA. (Christensen J, Gronborg TK, Sorensen MJ, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 2013 Apr 24;309(16):1696-703). (Response: Jacob Christensen PhD, Department of Neurology, Aarhus University Hospital, E-mail: Jakob@farm.au.dk).

COMMENT. Maternal exposure to valproate during pregnancy is associated with a small (<5%) but significantly increased risk of autism spectrum disorder and childhood autism in the offspring, even after adjusting for effects of parental epilepsy and

The risks of valproate in women of childbearing potential (15-44 years) may outweigh the benefits. Given the evidence linking fetal valproate exposure to congenital malformations, cognitive impairments (Pediatr Neurol Briefs 2013 Apr;27(4):31), and autism, the use of valproate in potentially parous women should be minimized, restricted to cases with no available alternative treatment, and only introduced (in low dosage) after potential risks are fully explained. (Meador KJ, Loring DW. Editorial. Risks of in utero exposure to valproate. JAMA 2013 Apr 24;309(16):1730-1).

**Fetal Growth and Risk of Autism.** Investigators at the University of Manchester, UK, and other centers studied the relationship between fetal growth and autistic spectrum disorder (ASD). Deviance in fetal growth at either extreme and preterm birth are strong independent risk factors for later ASD, especially with intellectual disabilities. Genetic and environmental factors might influence fetal growth and predispose to ASD. (Abel KM, et al. Deviance in fetal growth and risk of autistic spectrum disorder. Am J Psychiatry 2013 Apr 1;170(4):391-8).

**ANTIEPILEPTIC DRUG DISPOSITION IN PREGNANCY**

Investigators at the Karolinska Institute, Stockholm, Sweden; and centers in Oslo, Norway, and Milan, Italy, reviewed the literature on gestational effects on pharmacokinetics of older and newer antiepileptic drugs (AEDs). Absorption, distribution, metabolism, and elimination may be affected depending on the type of AED. A pronounced decline in serum concentrations is seen for AEDs eliminated by glucuronidation (UGT), especially lamotrigine. Serum levels of AEDs cleared mainly through the kidneys, e.g. levetiracetam, decline significantly. In contrast, carbamazepine is affected only marginally by pregnancy. Data on newer drugs are either lacking or vary widely: pregabalin, lacosamide, retigabine, and eslicarbazepine acetate. In general, declining serum concentrations in pregnancy are associated with deterioration in seizure control. AED serum monitoring and dose adjustment based on falling levels may be important, particularly when a patient’s levels are titrated to the lowest effective AED dose and serum concentration before pregnancy. (Tomson T, Landmark CJ, Battino D. Antiepileptic drug treatment in pregnancy: Changes in drug disposition and their clinical implications. Epilepsia 2013 Mar;54(3):405-14). (Response: Torbjorn Tomson, Department of Neurology, Karolinska University Hospital, Stockholm, Sweden. E-mail: trobjorn.tomson@karolinska.se).

**COMMENT.** Pharmacokinetic changes during pregnancy are rapid and labile and have a profound effect on the management of epilepsy. The risks of uncontrolled seizures are weighed against potential teratogenic effects of AEDs.